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  ABSTRACT 
Angiogenesis is the process of new blood vessel development by endothelial cells 
from pre-existing vasculature; however, abnormal angiogenesis contributes to the 
pathogenesis of many disorders such as cardiovascular diseases, cancer, and chronic 
inflammation. Angiogenesis in atherosclerotic plaques contributes to their instability and 
therefore increases the risk of plaque rupture and thrombus formation.  Sparstolonin B 
(SsnB) is a novel bioactive compound isolated from Sparganium stoloniferum, an herb 
that has been used historically in the Chinese herbal medicine “SanLeng” as an herbal 
remedy for the treatment of several inflammatory diseases.  In this study, we have 
explored the anti-angiogenic properties of SsnB in vitro. In cell culture, SsnB induced 
rapid changes in the morphology of human umbilical vein endothelial cells (HUVECs). 
After 6 hours, SsnB induced endothelial cell actin stress fibers, increased cell 
perimeter/area ratio, and enhanced formation of focal adhesions. These effects occurred 
in a dose-dependent manner in which the maximum effect was at 100M SsnB. In 
addition, we have also analyzed early response gene expression in response to 100 M 
SsnB. Our data show that SsnB blocked the up-regulation c-Myc and c-Fos, which 
occurred in response to addition of vehicle control (DMSO). These results imply that 
alteration of endothelial cell morphology and change of early response gene regulation 
may play a role in the anti-angiogenic effects induced by SsnB. 
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CHAPTER 1 
INTRODUCTION 
1.1 Atherosclerosis 
Atherosclerotic cardiovascular disease is the first leading cause of morbidity and 
mortality in the United States, where cardiovascular risk assessment accounts for <50% 
of the variability in risk. Approximately 85% of middle-aged susceptible subjects have 
significant coronary atherosclerosis, which remains silent for decades until it finally 
presents with plaque rupture and thrombosis. In fact, myocardial infarction (MI) occurs in 
62% of men and 42% of women with coronary atherosclerosis regardless of race or 
ethnicity (Weintraub et al. 2008). Many risk factors have been determined to be 
associated with progressive atherosclerotic disease, including hypertension, obesity, 
diabetes, smoking, and hyperlipidemia. Hyperlipidemia is defined as an elevation of low-
density lipoprotein (LDL) cholesterol level, which is directly related to plaque formation 
(Victor et al. 2009).  
In the normal physiological state, many of the large human arteries possess a 
microvasculature in their adventitial layer called the vasa vasorum. Large blood vessels 
are composed of three layers: tunica media, tunica intima, and tunica adventia. The tunica 
intima is the inner layer of the blood vessel wall and consists of endothelium. The middle 
layer of the vessel wall, tunica media, contains circularly arranged smooth muscle cells. 
The outer layer is the tunica adventia, which is made of collagen fibers mixed with nerve 
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fibers, lymphatic vessels, and microvasculature. Normal vasa vasorum originate from 
coronary artery branch points at regular intervals and run longitudinally along the vessel 
wall as is illustrated in (Figure 1.1). 
Detection of early development of atherosclerosis can be accomplished using a 
variety of screening and diagnostic tests such as electrocardiogram, stress test, CT scan or 
arteriography. Moreover, biomarkers levels within the plasma can be helpful to diagnose 
atherosclerosis; for example elevated plasma concentrations of both fibrinogen and C-
reactive protein (CRP), which are acute phase proteins released in response to 
inflammation (Kaperonis et al. 2006). 
 
 
Figure 1.1 Illustration of Vasa Vasorum in Large Blood Vessel (Seeley et al. 
2007) 
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1.2 Plaque Formation 
Atherosclerosis mainly affects wall thickness of medium and large arterial blood 
vessels. Endothelial dysfunction has been thought to have a significant role in 
pathogenesis of atherosclerosis. Also, overproduction of reactive oxygen species (ROS) 
has been determined to be related to the development of atherosclerosis (Davignon and 
Ganz 2004). 
Endothelial damage or dysfunction will increase the permeability of the 
endothelium, known as endothelial activation. The infiltration of LDL into the inner wall 
of blood vessels, the arterial intima, will increase due to impaired endothelial function. 
Over time, substances such as LDL, cholesterol and fatty materials will accumulate at 
damaged areas as shown schematically in (Figure 1.2). LDL will be oxidized by reactive 
oxygen species to form oxidized-LDL (ox-LDL). Then, ECs from the damaged sites will 
initiate immune responses and release chemoattractants to attract monocytes from the 
blood and induce an inflammatory reaction. Monocytes will differentiate into 
macrophages in response to oxidized-LDL stimulation. The first immune response will 
trigger a further cycle of immune responses. Macrophages will continue to take up and 
digest the modified cholesterol molecules. Macrophages are not able to clear the 
oxidized-LDL from the intima, although these white blood cells are intended to play a 
protective role. This process ends with formation of foam cells and eventual generation of 
fatty streaks, which are found in human aorta during the first decade of life (Lusis 2000). 
Vascular smooth muscle cells (VSMC) begin to proliferate and migrate from the 
media to the intima. The initial lesion progresses into an advanced plaque with a fibrous 
cap, overlying a necrotic lipid core. The fibrous cap acts as a protective layer between the 
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lesion and the lumen of the blood vessel. The media and neo-intima will be subjected to a 
restriction of oxygen supply and nutrients, and the hypoxic environment may lead to 
expression of Vascular Endothelial Growth Factor (VEGF) and other angiogenic 
regulators that stimulate angiogenesis, thereby promoting plaque growth. Various 
research studies have identified intra-plaque hemorrhage as a critical factor in 
atherosclerotic plaque growth and destabilization (Sluimer etal.2009; Khurana et al. 
2005; Di Stefano et al. 2009; Virmani et al. 2005; Seeley et al. 2007). 
 
 
 
The composition of a plaque largely determines the risk of rupture for fibrous 
caps, which may cause an acute ischemic event, for example a myocardial infarction or 
stroke (Owens et al. 2004). Thrombus formation is a significant clinical complication of 
atherosclerosis resulting from rupture of an unstable atherosclerotic plaque, in which 
Figure 1.2 Illustration of atherosclerotic plaque formation (Choudhury, Fuster 
and Fayad 2004) 
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formation of microvessels (angiogenesis) contributes to the development of plaques and 
increases the risk of plaque rupture (Sluimer et al. 2009). 
1.3 Endothelial Cell Function 
Endothelial cells play a wide variety of critical roles in controlling vascular 
function. It has been proposed that hemangioblasts, as common progenitors of 
endothelial, hematopoietic cells, and angioblasts, differentiate from the mesoderm in the 
embryo and VEGF receptor is expressed early in these progenitors (Hirashima 2009). 
VEGF is the most critical driver of vascular formation, as it is required to initiate the 
formation of immature vessels by vasculogenesis or angiogenic sprouting. Endothelial 
cells interact with circulating cells and cells present in the vascular wall including smooth 
muscle cells, during homeostasis. Being at the interface between blood and tissue, 
endothelial cells are most susceptible to changes in blood composition and in blood ﬂow. 
Endothelial dysfunction could dispose specific areas of the vasculature to coagulation, 
inﬂammation and vasoconstriction. Endothelial dysfunction is certainly a key initiating 
event in several pathological conditions, including atherosclerosis (Michiels 2003).  
VEGF plays a major role in all aspects of vascular development, including 
endothelial cell proliferation, migration, and survival. Endothelial cells are the main 
regulators of vascular development. The biological effects of VEGF are mediated by two 
receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2.  It has been determined that 
VEGF is a survival factor for endothelial cells, both in vitro and in vivo. In vitro,VEGF 
prevents apoptosis induced by serum starvation where this activity is mediated by the 
phosphatidylinositol (PI)-3 kinase–Akt pathway. VEGF also induces expression of the 
anti-apoptotic proteins Bcl-2 and A1 in endothelial cells. In vivo, the prosurvival effects 
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of VEGF are developmentally regulated. It has also been shown that inhibition of VEGF 
results in extensive apoptotic changes in the vasculature of neonatal but not adult mice 
(Ferrara,Gerber and LeCouter 2003). 
1.4 Physiological and Pathological Angiogenesis 
Angiogenesis is the process of new blood vessel development from pre-existing 
vasculature. This process involves endothelial cell proliferation, degradation of the 
basement membrane and surrounding extracellular matrix, cell migration, and 
tubulogenesis. Angiogenesis consists of four stages: initiation, progression, 
differentiation, and maturation. It is controlled by a complex regulatory system composed 
of pro-angiogenic and anti-angiogenic factors, among which the VEGF family plays a 
key role through its pro-angiogenic activity, in addition to other factors and enzymes 
(Hoeben et al. 2004; Bussolino et al. 1997; Carmeliet et al. 2003). De novo blood vessel 
formation, or vasculogenesis, is an important process for the survival of living organisms 
in the embryonic state. In the adult state, physiological angiogenesis plays an essential 
role in wound healing, growth of the uterine lining, and the female reproductive   cycle. 
However, excessive, insufficient or abnormal angiogenesis contributes to the 
pathogenesis of many disorders such as cardiovascular diseases, cancer, arthritis, 
psoriasis, retinopathy, and inflammation (Khurana et al. 2005; Carmeliet et al. 2003; 
Kaiser et al. 1999). 
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1.5 Anti-angiogenic Therapy and Sparstolonin B Effect 
Anti-angiogenic therapy has been recognized as a promising approach recently 
particularly in cancer treatment. This approach has advantages over conventional 
anticancer therapy because the therapy does not directly target the tumor but inhibits the 
development of blood vessels by targeting the endothelial cells. Thus, anti-angiogenic 
therapy is indirectly cytotoxic to the tumor cells (Hoeben et al. 2004; Somani et al. 2013). 
This new approach is still questionable as a treatment for atherosclerotic disease because 
angiogenesis in atherosclerosis is more complex and depends on disease severity 
(Khurana et al. 2005); however, some previous work has demonstrated effective 
treatment procedures to inhibit neovascularization in atherosclerotic plaques that will 
increase their stability and thus, decrease thrombosis (Stefanadis et al. 2007). 
 
Figure 1.3 Illustration of angiogenesis process (Griffioen and Molema 2000). 
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Most chemotherapeutic drugs are considered have some anti-angiogenic activity. 
This activity was demonstrated at a lower dose of chemotherapeutic drugs, including 
cyclophosphamide, paclitaxel, doxorubicin, and vincristine, than would be required to 
target tumor cells. In addition, many anti-angiogenic agents showed a successful 
suppression of angiogenesis especially within tumors such as anti-VEGF monoclonal 
antibody and tyrosine kinase inhibitors. Moreover, EGF receptor inhibitors have been 
shown to suppress VEGF expression through blocking the VEGF-R2 receptor signaling 
(Scappaticci 2002). Angiogenesis gene therapy is another promising approach that is 
directed to tumor endothelial cells and their microenvironment. The use of gene therapy 
that delivers anti-angiogenesis genes has shown promise in preclinical models in mice. 
The expression of EC specific cell surface molecules like vascular endothelial growth 
factor receptor (VEGFR), E selectin or angiogenic growth factors (VEGF, FGF, PDGF) 
produced by tumor cells can be inhibited by specific antibodies, antisense RNA, or gene 
specific siRNA. The targeted gene therapy can be achieved by using either viral vectors 
or nanoparticles to target anti-angiogenic genes to tumor vasculature (Tandle, Blazer, and 
Libutti 2002). 
The Sparganium stoloniferum plant has been used traditionally in Chinese 
medicine for the treatment of cancer. Extracts and other isolated chemical compounds 
from this herb, including a sucrose ester, a phenylpropanoid glycerol, carboxylic acid 
esters, and a phenylpropanoid glycoside, possess potent anti-cancer effects. It is already 
known that anti-tumor agents often show the ability to inhibit angiogenesis, and 
Sparstolonin B (SsnB) is one of the active compounds of this plant that has anti-tumor 
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activity. Also, SsnB has been identified as a compound that possesses anti-angiogenic 
activity in addition to its anti-inflammatory properties (Bateman et al. 2013). 
SsnB is a newly described polyphenolic compound isolated from the tubers of 
Sparganium stoloniferum. It has been identified as a compound containing the core 
structures of both xanthone and isocoumarin using NMR spectroscopy and X-ray 
crystallography (Liang et al. 2011) as shown in (Figure 1.5.1). The naturally occurring 
xanthones and isocoumarins possess anti-inflammatory, antioxidant, anti-atherosclerotic, 
and antitumor activities (El-Seedi et al. 2010; Fylaktakidou et al. 2004). Sparganium 
stoloniferum has been used historically in the Chinese herbal medicine “SanLeng” as an 
herbal remedy for the treatment of several inflammatory diseases.  
 
 
 
 
 
 
 
 
 
 
Cytotoxicity measurements of SsnB show that the compound is safe to use in 
concentrations up to 100M in different cell types, which include mouse peritoneal 
Figure 1.4 Structure of SsnB (Liang et al. 2011) 
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macrophages, human monocytic THP-1 cells, HUVECs, and human aortic smooth 
muscle cells (HASMCs).  
Recently, SsnB has been successfully synthesized based upon its well- known 
xanthone core structure through development of a practical method consisting of 
sequential chemical reactions to yield the final SsnB product. It has been shown that the 
synthetic SsnB shares identical structure with the plant-derived SsnB using HPLC and 
NMR analysis. The final product has purity greater than 99%, which has been achieved 
using HPLC and mass spectrometry techniques to maintain reproducibility and to control 
the purity (Hu et al. 2012).  
1.6 Published Research Studies 
In previous research, it has been demonstrated that SsnB is a selective Toll-like 
receptor antagonist (TLR2 and TLR4); it blocks TLR2- and TLR4-triggered 
inflammatory signaling in macrophages by inhibiting the recruitment of MyD88 to TIR 
domains of TLR2 and TLR4 but does not block signaling in response to TLR3 and TLR9 
ligands (Liang et al. 2011). Toll-like receptors are expressed by macrophages, dendritic 
cells, and many other cell types. TLRs are known for their activity as the first line of 
defense against invading pathogens such as bacteria and viruses (Kumar, Kawai and 
Akira 2011). The therapeutic consequences of blockage of excessive TLR signaling are 
being demonstrated for many inflammatory diseases including inflammatory 
cardiovascular diseases. In addition, it has been shown that SsnB suppressed multiple 
signaling pathways downstream of TLR2 and TLR4 activation including MAPK and NF 
B pathways (Liang et al. 2011; Liang et al. 2013). 
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According to a previously published paper, it has been demonstrated that SsnB 
possesses anti-inflammatory effects on vascular endothelial cells. SsnB showed a 
suppressive effect on lipopolysaccharide (LPS)-induced expression of interleukin (IL)-1b 
and monocyte chemoattractant protein 1 at the transcriptional and translational levels in 
HUVECs (Liang et al. 2013). LPS is considered the major portion of the outer membrane 
of Gram-negative bacteria, which is an important pathogenic stimulus, in addition to 
being a ligand for Toll-like receptor (TLR4) (Wiedermann et al. 1999). Moreover, LPS in 
the blood directly promotes vascular inflammation via the activation of resident cells 
such as monocytes and endothelial cells (Roth et al.). 
Published data from a previous study suggests that SsnB targets endothelial cells 
and inhibits angiogenesis by interfering with crucial steps in the process (Bateman et al. 
2013). The data shows that SsnB is an inhibitor of endothelial cell morphogenesis and 
cell migration. In addition, the results suggest that SsnB is able to inhibit cell 
proliferation through arresting the cell cycle in the G0/G1 phase. Microarray data showed 
differential expression of important genes involved in angiogenesis in response to SsnB 
treatment, including genes in pathways associated with the cytoskeleton, cell 
proliferation, and cell cycle. Using the chick chorioallantoic membrane (CAM) assay, an 
ex vivo angiogenesis assay, it was demonstrated that SsnB causes an inhibition of blood 
vessel formation in the chick embryos, where the vessels in SsnB-treated embryos are 
shorter in length and show reduced branch formation compared to control groups 
(Bateman et al. 2013). 
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1.7 Specific Aims 
We hypothesize that SsnB will exert its anti-angiogenic effects by changing the 
cell cytoskeleton, enhancing focal adhesion formation, and interfering with early 
response gene up-regulation. 
Specific Aim 1  
To test the hypothesis that SsnB influences endothelial cell morphology and 
cytoskeletal organization. For this purpose, we will use immunofluorescence analysis of 
actin filaments and microtubules. 
Specific Aim 2  
To test the hypothesis that SsnB promotes focal adhesion formation in HUVECs.  
Immunofluorescence analysis for focal adhesions will be used to investigate the anti-
angiogenic effect of SsnB. 
Specific Aim 3  
To test the hypothesis that SsnB interferes with early response gene up-regulation. 
Immunoblot analysis and real time qRT-PCR will be used to examine the changes in 
protein and mRNA expression of c-Myc, c-Fos, and c-Jun due to the effect of SsnB 
treatment. 
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CHAPTER 2 
THE EFFECTS OF SPARSTOLONIN B ON CYTOCKELETON 
ARRANGEMENT AND MORPHOLOGY OF ENDOTHELIAL CELLS 
2.1 Introduction 
Since inhibition of angiogenesis is associated with changes in cell motility and cell 
proliferation, we investigated in this work the effect of SsnB on the cytoskeleton 
including actin filaments, microtubules, and focal adhesions. The actin cytoskeleton has a 
vital role in various cellular processes such as migration and cytokinesis. In addition, 
abnormalities in actin dynamics are associated with many pathological disorders such as 
cancer. Actin filaments form stress fibers that contribute to cell migration; however, other 
studies observed that stress fibers are more prominent in stationary cells suggesting that 
stress fibers may inhibit cell migration under specific conditions (Tojkander et al 2012; 
Burridge 1981). Microtubules are structural components of the mitotic spindle, and 
microtubule dynamics play an important role in several cellular processes including 
intracellular trafficking, cell migration and cell division. Inhibition of microtubules 
results in blocking of cell cycle progression in mitosis, whereas prolonged mitotic arrest 
triggers various apoptotic pathways (Rai et al. 2012). In addition, focal adhesions, 
dynamic protein complexes that connect the cytoskeleton of a cell to the extracellular 
matrix, play an essential role in vital biological processes including cell motility, cell 
proliferation and differentiation. Anti-angiogenic agents have been shown to diminish 
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cell migration and to increase attachment of cells to their substrate (Petit and Thiery 
2000).  
2.2 Materials and Methods 
Compounds—Sparstolonin B (SsnB) was purified from the plant Sparganium 
stoloniferum and its structure identified with isocoumarin core using NMR spectroscopy 
and X-ray crystallography (Liang et al. 2011).  Recently, the compound has been 
synthesized and tested for efficacy (Hu et al. 2012). For the in vitro experiments, SsnB 
was dissolved in DMSO (74.5 mM and 100 mM stock solutions) and freshly diluted in 
HUVEC medium before use. 
Cells—Human umbilical vein endothelial cells (HUVECs) were obtained from 
Lonza (Hopkinton, MA) and cultured on petri plates (100 X 20 mm) coated with 0.1% 
gelatin. HUVECs were cultured in endothelial cell medium supplemented with 10% fetal 
bovine serum (FBS) and endothelial cell mitogen / growth supplement (Biomedical 
Technologies, Stoughton, MA).  The endothelial cell medium was replaced every 2-3 
days, and the cells were passaged after complete confluence was reached. Cells were 
used between third and fifth passage. 
Immunofluorescence analysis of the cytoskeleton—HUVECs were trypsinized 
from confluent plates and then grown overnight on 0.1% gelatin-coated multi-well 
chamber slides with initial seeding density of 5,000 cells per well. Next, various 
concentrations of SsnB (1, 10, and 100 µM) or vehicle control (0.1% DMSO) were added 
to the cells in assigned wells.  After 6 hours of treatment, cells were fixed with 2% 
formaldehyde in, cytoskeleton buffer with sucrose (CBS) for 20 minutes and 
permeabilized with PBS- 0.1%Triton X-100 for 10 minutes. Fixed cells were washed and 
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incubated at room temperature for 30 minutes with rabbit anti- /-Tubulin antibody 
(Cell Signaling Technologies), 1:50. After washes, cells were incubated with 1:100 
Rhodamine Red X (RRX)-conjugated donkey anti-rabbit antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA) together with the F-actin- binding 
Alexa Fluor® 488 phalloidin (Invitrogen/ Life Technologies). Coverslips were then 
mounted with Dako fluorescent mounting medium. Samples were analyzed on a laser 
scanning confocal microscope (Zeiss LSM 510 META) in the Instrumentation Resource 
Facility (IRF) at the USC School of Medicine. Cells were observed with a 40X objective 
lens, using a FITC filter to visualize F-actin and a CY3 filter for tubulin. Results were 
observed in four separate experiments. 
Immunofluorescence analysis of focal adhesions—HUVECs were trypsinized 
from confluent plates and then grown overnight on 0.1% gelatin-coated multi-well 
chamber slides with initial seeding of 5,000 cells per well. SsnB treatment of various 
concentrations (1, 10, and 100 µM) or vehicle control (0.1% DMSO) was added to the 
cells in assigned wells.  After 6 hours of SsnB treatment, the cells were fixed with 4% 
formaldehyde/CBS for 20 minutes and permeabilized with PBS- 0.5% Triton X-100 for 
10 minutes. After several washings, cells were incubated with mouse anti-vinculin 
antibody (hVIN-1; Novus Biologicals), 1:400, at room temperature for 30 minutes to 
stain focal adhesions. Then, cells were incubated with 1:100 RRX-conjugated donkey 
anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) in 
addition to actin staining as described previously. The slide was then cover slipped using 
Dako fluorescent mounting medium, and the cells were observed on a laser scanning 
confocal microscope (Zeiss LSM 510 META) with a 40X objective lens using the FITC 
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filter for F-actin and the CY3 filter for vinculin. Image-Pro Plus software was used to 
analyze the images. First, the brightness and contrast of images were uniformly adjusted. 
Images were thresholded by histogram-based segmentation to identify focal adhesion 
pixels, the bright objects. The size of objects counted as focal adhesions was between 20 
and 250 pixels in area, and the total area of focal adhesions was quantified in 
approximately 100 cells for each treatment.  Also, the same software was used to quantify 
cell area and cell perimeter. The threshold for images was identified to separate cell body 
and background region. After thresholding the image, the regions less than 10 pixels in 
area and perimeter are discarded. The brightness and contrast were maintained constant 
for all images for each measurement (focal adhesion area or cell perimeter/cell area). 
Results are representative of those obtained in three separate experiments. 
Statistical Analysis—Data were represented as mean ± SD for each group. 
Comparisons among mean values of the treatment groups and control group were done 
using one-way and two-way ANOVA. Holm-Sidak test was used for comparisons 
between groups for the data that showed significance by ANOVA (p<0.05). 
2.3 Results 
 SsnB influences endothelial cell morphology and cytoskeleton organization—
SsnB has been shown to interfere with endothelial cell migration and proliferation 
(Bateman et al 2013). Since cytoskeleton is directly related to migration and proliferation, 
we investigated the effect of SsnB on endothelial cell cytoskeleton. In addition, since 
changes in cell shape are often associated with changes in motility, the effects of SsnB on 
endothelial cell morphology were investigated. We also attempted to examine 
microtubule organization, but our staining procedure was unsuccessful as presented in 
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[Figure 2.1]. Both control cells and SsnB treated cells showed disconnected microtubules 
(B) whereas cells used for / tubulin antibody titration showed well organized 
microtubules (A). SsnB-treated cells had more actin stress fibers across the cell body than 
control cells, and this effect was more intense at 100M concentration as can be observed 
qualitatively in [Figure 2.2]. Also, SsnB treatment resulted in a significant dose 
dependent increase in cell perimeter/cell area at concentrations 1, 10, 100 M (p < 0.05 
ANOVA, Sidak’s test) [Figure 2.3].  
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, we investigated cell shape and found that SsnB-treated cells tended to 
be more irregular in shape at high concentrations than control cells [Figure 2.4]. Cell 
shape was defined using the equation (4 x cell area/ (cell perimeter) 
2
), where 1 indicates 
 
A B
Figure 2.1 Microtubules in HUVECs. (A) Cells were stained for microtubules in red 
using / tubulin antibody for the purpose of antibody titration, to determine the ideal 
concentration for the experiment. (B) SsnB treated cells and control cells were stained 
for microtubules using 1:50 / tubulin antibody. Cells in (B) show fragmented 
microtubules in both control and treated groups.     
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a perfect circle and smaller values indicate a more irregular shape. Our data suggest that 
SsnB may affect endothelial cell migration by altering cytoskeletal organization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
 Figure 2.2 Representative example of SsnB effect on cytoskeletal organization of 
endothelial cells. HUVECs adherent to gelatin were exposed to 1 M, 10 M, and 100 
M concentrations of SsnB for 6 hours. SsnB induces stress fibers in treated cells, and 
the highest concentration induces the maximum effect. Green stained for F-Actin 
filaments, and scale bar = 20m. n = 100 cells per group. 
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** **
***
Figure 2.3 SsnB effect on HUVEC morphology. Treated cells exhibit a significant 
increase in cell perimeter to area ratio compared to control. **p<0.05 vs. vehicle 
control, Sidak’s test. *** p<0.001 vs. vehicle control, Sidak’s test. n = 100 cells per 
group, error bars correspond to +1 SD.  
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Figure 2.4 SsnB effect on HUVEC shape. Treated cells demonstrate insignificant 
increase in shape irregularity compared to control group where the equation (4 x cell 
area/ (cell perimeter)
2
) was used to calculate cell shape. The closest values to 1 
indicate more rounded cells. Data are calculated from more than 100 cells for each 
group. Error bars indicate standard deviation. 
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SsnB promotes focal adhesion formation—We investigated the effect of SsnB on 
focal adhesions due to their important role in cell migration. As presented in [Figure 2.5], 
endothelial cells show staining for focal adhesions in addition to actin filaments. Figure 
2.6 shows representative results from focal adhesion staining of HUVECs. Cells treated 
with SsnB showed an enhanced formation of focal adhesions in a dose-dependent manner 
at concentrations of 1, 10, and 100M. The results are statistically significant (p<0.05 
ANOVA) even though they show high variability. These data suggest that SsnB 
treatment may increase attachment of endothelial cells to their substrate by increased 
formation of focal adhesions, consistent with previously published observations of 
impaired cell migration in SsnB treated HUVECs after 6 hours of treatment (Bateman et 
al. 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.5 Focal adhesions in HUVECs. Control and SsnB treated HUVECs were 
stained with Alexa Fluor® 488 phalloidin (Green) for actin filaments, and stained 
with anti-vinculin antibody and RRX-labeled secondary antibody (Red) for focal 
adhesions.  
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Figure 2.6 SsnB promotes focal adhesion formation. Treated cells show dose-
dependent increase in focal adhesion area (p<0.05 ANOVA) with presence of high 
variability in the results obtained. The results were not significant using Holm-Sidak 
test to compare treated groups to control. n = 100 cells per group, error bars indicate 
+1 SD. 
 22 
 
CHAPTER 3 
EFFECTS OF SPARSTOLONIN B ON THE BIOCHEMICAL 
COMPONENTS OF ENDOTHELIAL CELLS 
 
3.1 Introduction  
In an effort to determine how SsnB inhibits angiogenesis at the molecular level, 
we have investigated the expression of immediate early response genes such as c-Fos, c-
Jun, and c-Myc. Early response genes are a set of genes that are induced in response to 
both cell-extrinsic and cell-intrinsic signals and do not require de novo protein synthesis 
for their expression (Fowler et al. 2011). The AP-1 protein family, including c-Fos and c-
Jun, is associated with cell proliferation through their ability to regulate the expression 
and function of cell cycle regulators. The expression of c-Myc is significant for 
endothelial cell proliferation, migration, and therefore angiogenesis. Previously published 
cancer studies demonstrate an important rule of c-Myc and c-Jun in tumor angiogenesis; 
these oncogenes possess the ability to suppress the expression of anti-angiogenic factor 
thrombospondin-1 (TSP-1) to provoke angiogenesis in progressed tumors. These genes 
contribute effectively to angiogenesis in various tumor types, and the same concept can 
be extended to angiogenesis in plaques (Vleugel et al. 2006; Baudino et al. 2002; 
Shaulian and Karin 2001; Deed et al. 1997). 
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3.2 Materials and Methods 
Compounds—Sparstolonin B (SsnB) was purified from the plant Sparganium 
stoloniferum as described in a previously published paper (Liang et al. 2011).  Recently, 
the compound has been synthesized and tested for efficacy (Hu et al. 2012). For the in 
vitro experiments, SsnB was dissolved in DMSO (74.5 mM and 100 mM stock solutions) 
and freshly diluted in HUVEC medium before use. 
Cells—Human umbilical vein endothelial cells (HUVECs) were obtained from 
Lonza (Hopkinton, MA) and cultured on petri plates (100 X 20 mm) coated with 0.1% 
gelatin. HUVECs were cultured in endothelial cell medium supplemented with 10% fetal 
bovine serum (FBS) and endothelial cell mitogen / growth supplement (Biomedical 
Technologies, Stoughton, MA).  The endothelial cell medium was replaced every 2-3 
days, and the cells were passaged after complete confluence was reached. Cells were 
used between third and fifth passage. 
Immunoblot analysis— HUVECs were cultured in 100 X 20 mm polystyrene 
culture plates coated with 0.1% gelatin to approximately 80% confluence. Cells were 
treated with 100M SsnB for different incubation times (1 hr, 2 hrs, and 3 hrs), and 
control cells were incubated with0.1% DMSO vehicle for the same time intervals.  After 
lysing cells of each group with 200 l Berk’s lysis buffer (BLB), total protein amount 
was measured using a DC (detergent compatible) protein assay (Bio-Rad Laboratories) in 
which bovine serum albumin (BSA) was used as the protein standard.  Thirty micrograms 
of total protein from each sample were mixed with loading dye buffer, boiled, and 
electrophoretically separated on 10% SDS polyacrylamide gels. Proteins were 
electrotransferred to PVDF membranes (Bio-Rad). Membranes were blocked in 5% 
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nonfat milk in Tris-buffered saline containing 0.05% Tween (TTBS) and incubated 
overnight with primary rabbit antibodies against c-Myc, c-Fos (Cell Signaling 
Technologies) or c-Jun (Santa Cruz Biotech), at 1:1000 dilutions in 1% milk-TTBS. After 
washings, membranes were incubated in 1:3000 dilution of horse-radish peroxidase 
(HRP)-conjugated goat anti-rabbit antibody (Bio-Rad) in 1% milk-TTBS. 
Immunoreactive band specificity was determined by enhanced chemiluminescence 
detection (Pierce). After initial probing, membranes were stripped with a buffer 
containing 0.6M Tris-Cl, 2% SDS, 0.7% -mercaptoethanol at room temperature for 30 
min, and then reprobed with (1:1000) -actin antibody (MediMabs, Canada) as a loading 
control. Results are representative of three separate experiments.  
Densitometric measurements of Western blots—Image Pro Plus 7 software was 
used to measure the density of the imaged bands. The brightness and contrast of the blot 
image were adjusted to separate the bands, appearing as bright objects, from the 
background. The average intensity of each band was measured. The experimental bands 
were normalized to -actin bands, and then the ratio between the normalized value of 
each band and the vehicle control (at 0 hour) was obtained. The ratio represents a 
quantitative measurement of c-Myc protein expression.   
Real Time- PCR— HUVECs were chosen for real time PCR from 90% confluent 
plates (100 X 20 mm polystyrene, tissue culture-treated petri plates coated with 0.1% 
gelatin). Cells were trypsinized and seeded (400,000 cells per well) overnight in 6 well 
polystyrene culture plates coated with 0.1% gelatin. Half of the wells received HUVEC 
medium containing 100 M SsnB, and the remaining plates received vehicle control 
(0.1% DMSO in complete growth medium).  The plates were incubated for several time 
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intervals (1 hr, 2 hrs, and 3 hrs) to allow SsnB to have an effect on the expression of early 
response genes.  Following incubation, the cells were lysed using Trizol reagent (Life 
Technologies) according to the manufacturer’s instructions. Total RNA was extracted 
using chloroform, and then samples were centrifuged (13,000 rpm) for 15 min at 4C. 
Approximately 350 l of aqueous layer was collected, and isopropanol was added to 
precipitate the RNA followed by centrifugation for 10 min under the same conditions. 
The RNA pellet was washed by addition of 1 ml of 75% ethanol and centrifuged at 
13,000 rpm for 5 min. The pellet was re-suspended in 30 l nuclease free water. The 
concentration of RNA was determined spectrophotometrically at 260 nm and the purity 
of RNA was assessed by measuring the 260 nm/ 280 nm ratio. First strand cDNA was 
prepared from the RNA with reverse transcriptase (iScript cDNA synthesis kit, BioRad). 
The RNA was amplified using c-Myc, c-Fos, or c-Jun primers (Qiagen) and iQ SYBR 
Green super mix (BioRad). One-step RT-PCR reactions were completed on the BioRad 
CFX Connect thermal cycler system in the Instrumentation Resource Facility at the USC 
School of Medicine.  The expression levels were normalized to the housekeeping gene 
GAPDH, and RNA levels were quantified and compared between groups with the 
relative Pfaffl method for c-Myc (Pfaffl 2001). In addition, we used the CT method for 
c-Fos and c-Jun to compare RNA levels between groups. Representative results from 
three separate experiments are shown. 
Statistical Analysis—Data were represented as mean +SD for each group. 
Comparisons among mean values of the treatment groups and control group were done 
using one-way and two-way ANOVA. Holm-Sidak test was used for pairwise 
comparisons between groups for the data that showed significance by ANOVA (p<0.05). 
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3.3 Results 
SsnB effects on early response gene expression— Western blot analysis was used 
to investigate the effect of SsnB on c-Fos, c-Jun, and c-Myc protein levels. We did not 
detect any signal for c-Fos protein, and it was hard to detect c-Jun signal because of the 
appearance of several nonspecific bands near the expected position of c-Jun. However, 
Western blot analysis showed that treatment with vehicle control (0.1% DMSO) resulted 
in increased expression of c-Myc protein which peaked at 2 hours and then diminished.  
This effect appeared to be abrogated by treatment with 100 M SsnB; however, the data 
did not reach statistical significance. For verification purposes we investigated the effect 
of SsnB on c-Myc mRNA levels. qRT- PCR analysis demonstrates a decrease in c-Myc 
gene expression after SsnB treatment compared to the control group, which supports the 
results obtained from immunoblot analysis (p<0.05 ANOVA, Sidak’s test) [Figure 3.1]. 
In addition, we investigated the effect of SsnB on c-Fos and c-Jun mRNA level. Our 
preliminary data shows that SsnB treated cells reveal a decrease in expression of both 
genes compared to the control group [Figure 3.2]. This reduction effect was significant 
for c-Fos (p<0.05 ANOVA, Sidak’s test), but it was insignificant for c-Jun. The data 
suggests that SsnB treatment may interfere with or inhibit up-regulation of c-Myc, c-Fos 
and c-Jun. This effect may relate to the inhibition of cell cycle progression by SsnB 
treatment, which has been demonstrated previously (Bateman et al. 2013). 
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Figure 3.1 SsnB effect on c-Myc expression. (A) Western blot analysis and quantitative 
densitometry of c-Myc protein expression. When data are normalized for protein loading 
(actin) and compared to control, c-Myc shows an apparent decrease in expression in 
SsnB-treated cells relative to control, which did not reach statistical significance. (B) 
Real Time-PCR shows a decrease of c-Myc mRNA expression (normalized to 
housekeeping gene GAPDH) in response to SsnB treatment (*p<0.05 ANOVA, Sidak’s 
test). All data represent three observations for each group and are expressed as mean 
values +SD; all groups were compared to 1hr vehicle control. 
A 
B 
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Figure 3.2 Effects of SsnB on relative c-Fos and c-Jun mRNA expression. Real 
Time-PCR shows a decrease in expression of both c-Fos and c-Jun mRNA 
(normalized to housekeeping gene GAPDH mRNA) in response to SsnB treatment. 
(A) c-Fos data were statistically significant at the 2-hr time point (*p<0.05 ANOVA, 
Sidak’s test); all groups were compared to 1 hr vehicle control. However, c-Jun data 
(B) were statistically insignificant. Data represent three observations for each group 
and are expressed as mean values +SD. 
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CHAPTER 4 
DISCUSSION 
In the present study, we sought to assess the anti-angiogenic effect of SsnB at the 
cellular and molecular level of endothelial cells. Our results demonstrate that HUVECs 
treated with high concentrations of SsnB (10 and 100 M) show an increase in formation 
of actin stress fibers compared to controls. Furthermore, our data shows that focal 
adhesion area, which is related to stress fiber formation, increased in cells treated with 
high SsnB concentrations. Qualitative analysis of focal adhesion formation was 
unreliable because of cell population variability; some cells were bigger in size than 
others, so it was hard to conclude a difference in focal adhesion formation between 
control and treated groups. Quantitative analysis was used where focal adhesion area per 
cell was determined and statistically represented as shown previously in [Figure 2.3.6]. 
These changes affect the morphology of endothelial cells. SsnB-treated cells demonstrate 
larger perimeter/cell area ratio than control cells, and become irregular in shape. Taken 
together, the results suggest that cells treated with SsnB increase their attachment to the 
substrate, which may play a role in inhibiting their migration, an essential process in 
angiogenesis. Actin stress fibers play an important role in cell migration; however, stress 
fibers contribute to cell adhesion as well through formation of stable actin bundles and 
focal adhesions (Tojkander et al. 2012). Previous work has shown that the tension and 
contractility of actin stress fibers can send signals that are important for focal adhesion
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maturation and dynamics (Johnson et al. 2007). These results support the data shown by 
Bateman et al. in a previous study that demonstrated inhibition of endothelial cell 
migration in a Transwell migration assay in response to SsnB treatment (Bateman et al. 
2013). 
Microtubules are structural components of the mitotic spindle, and microtubule 
dynamics play an important role in several cellular processes including intracellular 
trafficking, cell migration and cell division (Müsch 2004). The inhibition of microtubule 
assembly dynamics has been shown to be the mode of action for several clinically 
successful anticancer drugs including vinblastine and vincristine (Dumontet and Jordan 
2010; Singh et al. 2008). SsnB showed the ability to interfere with cell cycle progression 
in mitosis through down regulating some cyclins and cyclin-dependent kinases, 
regulatory proteins that control cell cycle progression, including CCNE2, CCNB1, 
CDC6, and CDC2. In our study, we examined whether SsnB could perturb microtubule 
assembly in vitro, but we did not obtain any meaningful results. The microtubules in 
stained cells, both control and SsnB treated, were fragmented and disconnected. We tried 
several approaches to determine why the anti-tubulin staining was unsuccessful. We tried 
to modify the staining procedure by using cold methanol as a fixative instead of 
formaldehyde.  We also tried to use different concentrations of permeabilization solution, 
PBS- 0.5%- 0.1 %Triton X-100. Moreover, we were careful to ensure that the cells were 
healthy by using a new passage for each experiment, but all ended with the same 
conclusion. However, we will try to determine whether the antibody itself is the source of 
the problem. Since there is an identified connection between microtubules and cell 
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division, which SsnB interferes with, we are planning to continue to investigate the effect 
of SsnB on microtubule assembly in the future. 
 We observed either reduced upregulation or downregulation of the early response 
genes, specifically c-Myc, c-Fos, and c-Jun, in HUVECs after SsnB treatment. The effect 
of SsnB on c-Myc was more powerful in this study because it affected both c-Myc 
protein and mRNA. Immunoblotting of c-Myc protein revealed a decrease of expressed 
protein in response to SsnB treatment relative to vehicle control, and data were confirmed 
by qRT-PCR. The c-Myc mRNA level was reduced. This could be due either to a 
decrease in transcription or to an increase in its mRNA degradation, which remains to be 
determined. c-Myc functions are necessary and sufficient for the entry of most cells into 
the DNA synthetic (S) phase of the cell cycle (De Alboran et al. 2001). Studies of c-Myc 
in cancer showed that c-Myc is essential for vasculogenesis and angiogenesis during 
development and tumor progression. Deletion of c-Myc has a lethal effect on c-Myc-
deficient embryos. c-Myc is also required for the proper expression of angiogenic factors 
such as VEGF; however, the precise mechanism by which c-Myc controls their 
expression is not resolved. Also, it is assumed that VEGF regulation by c-Myc to be 
indirect (Baudino et al. 2002). 
qRT-PCR analysis demonstrates a reduction of c-Fos and c-Jun mRNA levels 
between 1 and 2 hours after SsnB treatment, even though no corresponding protein 
expression data were obtained by immunoblotting. c-Fos and c-Jun, members of the AP-1 
protein family, have biological functions in controlling cell proliferation, survival and 
death. One of the major mechanisms that modulates AP-1 activity is the differential 
expression of AP-1 proteins in response to extracellular stimuli (Shaulian and Karin 
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2001). A study revealed new ways to block tumor angiogenesis by targeting Jun/AP-1, 
and established a functional, in vitro link between activated c-Jun and angiogenesis in 
breast cancer (Vleugel et al. 2006). Another study showed that the nuclear oncogene c-
Fos regulates c-Fos-induced growth factor/vascular endothelial growth factor D 
(Figf/VEGF-D). This regulation is involved in transformation and in regulation of cell 
growth and differentiation of various tissues. Also, it has been demonstrated that 
developed tumors in c-Fos deficient mice appear lacking in vascularization (Marconcini 
et al. 1999). 
In conclusion, our data demonstrates that early effects of SsnB on endothelial 
cells include promoting formation of stress fibers and focal adhesions, and reduction of 
early response gene expression. These events may contribute to the anti-angiogenic effect 
of SsnB. Future additional studies are required to fully understand the effect of SsnB on 
microtubule assembly, and to examine whether SsnB disrupts mitotic spindle and 
microtubule dynamics. Also, we would like to examine whether the effect on 
cytoskeleton is reversible after removing SsnB treatment in vitro. Moreover, we will 
investigate the effect of SsnB on c-Fos and c-Jun gene expression by using the Pfaffl 
method (Pfaffl 2001) to compare experimental genes and to the housekeeping gene.  
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APPENDIX A- SUPPLEMENTARY DATA 
HUVEC medium: 
446 ml  K12 Medium 
50 ml  FBS 
50 mg  Heparin 
50 mg  Endothelial Mitogen 
4 ml  Non-Essential MEM Medium 
 
Berk’s Lysis Buffer  (BLB) pH 7.5: 
1.211 g Tris base 
8.766 g NaCl 
0.186 g KCl 
2.099 g NaF 
6.48 g  -glycerophosphate 
0.184 g Na3VO4 
5 ml   Triton X-100 
5 ml  Nonidet P-40 
Up to 1 L H2O 
  
Cytoskeleton Buffer with sucrose (CBS) 
1.07 g  MES pH 6.1 
5.14 g  KCl 
0.30 g  MgCl 
0.37g  EGTA 
Sucrose added fresh on the day of use of the buffer to final 0.32 M. 
 
 
 
 
 
 
 
 
 
 
